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Abstract
Background: The value of liver-directed therapy (LDT) in patients with metastasic renal cell carcinoma (MRCC) is
still an active field of research, particularly in the era of tyrosinkinase inhibitor (TKI) therapy.
Methods: The records of 35 patients with MRCC undergoing LDT of metastasic liver lesions between 1992 and
2015 were retrospectively analyzed. Immediate postoperative TKI was given in a subgroup of patients after LDT for
metastasic lesions. Uni- and multivariate models were applied to assess overall survival (OS), progression-free
survival (PFS) and disease-free survival (DFS).
Results: Following primary tumor (renal cell cancer) resection and LDT, respectively, median OS was better for a
total of 16 patients (41 %) receiving immediate postoperative TKI with 151 and 98 months, when compared to
patients without TKI therapy with 61 (p = 0.003) and 40 months (p = 0.032). Immediate postoperative TKI was
associated with better median PFS (47 months versus 19 months; p = 0.023), whereas in DFS only a trend was
observed (51 months versus 19 months; p = 0.110).
Conclusions: LDT should be considered as a suitable additive tool in the era of TKI therapy of MRCC to the liver. In
this context, postoperative TKI therapy seems to be associated with better OS and PFS, but not DFS.
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Background
Renal cell carcinoma (RCC) is one of the most com-
mon tumors with an increasing incidence of approxi-
mately 85 new cases and 35 deaths per 100 000
reported in 2012 in Europe [1–3]. The majority of pa-
tients with RCC present with an early stage of their
disease, 20–30 % have synchronous metastases and
20–50 % of the patients develop metastasic disease
after primary tumor resection [4–7].
Most data exist for lung metastases which represent
the common sites of distant metastases [5, 8]. Although
it is less common, liver metastases were observed in
30–40 % of the patients with metastasic disease [5, 9].
Unfortunately, development of liver metastasis was gener-
ally considered as a poor prognostic factor and was fre-
quently associated with more widespread disease [10, 11].
That’s the reason why liver resections in these patients are
often single decisions and consequently, there is little
available literature on this topic. Although larger series
were published with a focus on non-colorectal/non-
neuroendocrine metastases, patients with RCC repre-
sent only a small subgroup and were not the focus of
these studies [10, 12].
Unfortunately, the prognosis is poor in MRCC with 5-
year survival ranging from 5 to 15 %, because chemother-
apy, radiotherapy or immunotherapy have almost no
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influence or showed limited response [6, 8, 9, 11, 13–16].
Since several years, antiangiogenic targeted therapies
(TT), particularly tyrosinkinse inhibitor (TKI) agents, have
become available and showed improved clinical outcomes
in large multicenter trials [17–21]. However, a majority of
patients treated with TT develop resistance to this drugs
and complete response remains extremely rare. Surgical
treatment if feasible is the only potentially curative treat-
ment option for patients with MRCC [7, 8, 22]. Complete
resection of metastatic lesions is consistently associated
with survival benefits as previous studies has noted
[23–25]. Thus, some authors reported 25–52 % five-year
survival rates in cases of MRCC with complete resection
and decreased risk of death from RCC [7, 8, 25–27].
However, little information has been available on the
utility and benefit of systemic treatment after complete
resection of metastatic lesions. There are only a few re-
ports with small patient numbers reporting low long-
term progression-free survival rates after metastasect-
omy [8, 23, 26, 27]. Most of the studies had a focus on
the adjuvant treatment with immunotherapeutic or
chemotherapeutic agents [6, 24, 28]. Therefore, un-
derstanding the role of surgery in the era of TKI
therapy - especially in the neoadjuvant and/or adju-
vant multimodal treatment setting - is of increasing
importance and interest.
In the present study, we examined besides the effi-
cacy of surgical therapy for MRCC - with a focus to the
liver - the different treatment regimens that were re-
ceived by patients with hepatic metastasized RCC after
surgical resections of metastases. In addition, we assessed
the effect of immediate postoperative TT on short- and
long-term outcome like survival, tumor recurrence and
morbidity in patients with MRCC following primary
tumor resection and liver-directed therapy, respectively.
Methods
Patient selection and study population
Medical records of patients undergoing liver-directed
therapy (liver-directed therapy - LDT) for histologically
proven RCC liver metastases (RCCLM) at the Depart-
ment of Surgery, University Hospital of Leipzig, be-
tween 1992 and 2015 were analyzed retrospectively.
The study was approved by the local ethical commis-
sion board from the University of Leipzig (AZ EK: 243-
14-14072014). Due to the retrospective design of the
study and accordingly national guidelines, the local
ethic committee confirmed, that informed consent was
not necessary from participants.
Inclusion criteria consist of patients with metastasic
RCC to the liver who underwent LDT. Only patients
with complete available follow-up data were included in
the study. Patients with extended and unresectable liver
tumors, peripheral diffuse metastasic disease, or diffuse
hepatic involvements of all liver lobes were excluded
from study. Resectable synchronous extra-hepatic site me-
tastases were no contraindications for study inclusion pro-
vided that the overall surgical strategy aimed to be
curative. All patients underwent staging examinations to
determine suitability and eligibility for surgery including
physical examination, serum laboratory tests, abdominal
ultrasound, computed tomography (CT) (abdomen/chest)
or magnetic resonance tomography. In some cases the
diagnosis of liver metastasis was confirmed by fine-needle
cytology or biopsy. The Karnofsky Performance Scale
(KPS) of our study population were not less than 80.
All cases of patients with RCCLM were discussed by a
multidisciplinary team to assess the indication and suit-
ability for surgery. The decision for use of neoadjuvant
and/or immediate adjuvant targeted therapy following
liver metastasectomy was made on an individual basis in
oncological tumor board and was not prospectively spe-
cified. With regards to survival analysis, patients who
are withdrawn from a study as well as patients who are
lost to follow-up or alive without the event occurrence
at latest follow-up were censored in the survival chart.
The primary aim of the present study was to assess
the effect of immediate postoperative TT/TKI therapy
on progression-free survival (PFS)/disease-free survival
(DFS) of patients with hepatic metastasized renal cell can-
cer who received metastasectomy of primary metastasic
lesions or liver-directed therapy of metastatic hepatic le-
sions, respectively. The secondary endpoint was to assess
the overall survival in the different treatment regimes.
Variables/data collection
Standard clinicopathological and demographic parame-
ters of the study population were collected including:
Patient age (years); gender (male versus female); body
mass index (kg/m2); oncological parameters (Eastern
Cooperative Oncology Group (ECOG) performance Sta-
tus (0–5)); primary tumor characteristics (tumor location
(right versus left kidney), T-stage (T1-T4), lymph node
stage (N0-N2), Fuhrman grading (low (1–2); high (3–4)),
histological subtype (clear cell, chromophobe, papillary/
other)); treatment of the primary tumor (type of surgery
(complete or partial nephrectomy). Variables were also
collected on the number (n), location (unilobular versus
multilobular); size (cm), weight (g) of hepatic lesions as
well as occurrence of liver metastases (synchronous
versus metachronous) as well as presence of extrahe-
patic metastases (yes versus no). A particular interest
applied with details of adjuvant TT/TKI therapy (yes
versus no) after occurrence of metastasic lesions and
liver resection. Additionally, the different TKI treat-
ment regimes, the onset and duration of TKI therapy
following liver-directed therapy as well as the efficacy
of TKI therapy were examined.
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Operative information including type of liver-directed
therapy (surgery, interventional procedure (ablation, elec-
troporation), operating time (minutes), intraoperative
transfusion (yes vs. no), red blood cell concentrate (RBCC),
fresh frozen plasma (FFP), application of vascular inflow
occlusion (Pringles manoeuvre: yes vs. no) and extent of
resection. Hepatectomy was classified as minor (less than
three segments) and major (three or more segments). Mar-
gin status (microscopically complete- R0, microscopic (R1)
and macroscopic involvement (R2)) was determined based
on final pathological assessment. Peri- and postoperative
collected data including length of intensive care unit (ICU)
stay (days), length of hospital stay (days), tumor recur-
rence, survival such as morbidity and mortality rate. Post-
operative complications are presented according to the
Clavien-Dindo-Classification (grade I to V). Therefore,
grades I and II were taken together as minor complications
and grade III-V as major complications. The perioperative
mortality was defined as 30-day mortality.
Overall survival (OS) was either calculated as the time
interval between primary tumor operation (renal cell
cancer resection) until latest follow-up/or death or sec-
ondary tumor operation (liver tumor therapy) until latest
follow-up/or death.
Disease-free interval (DFI) was calculated as the time
interval from liver-directed therapy until first recurrence
at any site. Progression-free survival (PFS) was calcu-
lated from time of resection of first metastases/start of
TKI therapy until time of progression/recurrence or last
follow-up/death. Disease-free survival (DFS) was calcu-
lated from date of liver-directed therapy to first recur-
rence, distant metastases, last follow-up or death.
Statistical analysis
All data are presented as either percentage, mean value
with range or median value with interquartal range (IQR).
Data were analyzed using Student’s t-test and Wilcoxon
rank sum test for continuous variables, and the chi-
squared test or Fisher’s exact test for discrete variables,
where appropriate. Disease-free survival, progression-free
survival and overall survival were examined using the
Kaplan-Meier Method and potential prognostic factors
were evaluated in univariate analysis by a two-sided log-
rank test. A multivariable Cox proportional hazard regres-
sion model was used to identify independent prognostic
factors for disease recurrence and survival/mortality. In-
cluded tested variables in Cox proportional hazard regres-
sion analysis were chosen according to the literature and
the primary/secondary aims of the study: immediate post-
operative targeted Therapy, ECOG performance status >1,
synchronous liver metastases and multiple liver metasta-
ses. P-values < 0.05 were considered statistically signifi-
cant. All data were analyzed by using SPSS software (SPSS
Inc., Chicago, Illinois, USA, version 19.0).
Results
General and oncological characteristics
The outcome of 35 patients (female = 11, male = 24) with
a median age of 65 years (IQR: 59–71) at time of LDT
was investigated.
The primary tumor location was nearly equally distrib-
uted between the patient collective (right kidney; 21
(60 %)/left kidney; 14 (40 %). Each patient underwent
curative surgery for the primary tumor: radical nephrec-
tomy in 31 patients (86 %) and partial nephrectomy in 4
patients (14 %). The majority of patients (60 %) had
lymph node metastases associated with the primary
tumor (N1; 40 %, N2; 20 %) and most primary tumors
were pathologic T2 or T3 lesions (T1: 20 %; T2: 25.8 %;
T3, 42.8 %; T4, 11.4 %). The primary tumor could be re-
moved completely in all patients. Fuhrman Grading was
low in most patients (grade 1: 2 patients (5.7 %); grade
2: 22 patients (62.9 %); grade 3: 9 patients (25.7 %); grade
4: 2 patients (5.7 %)). The final histology of the primary
tumor showed in all patients RCC, compromising a clear
cell subtype in 25 patients (71.4 %), followed by chromo-
phobe carcinoma in 6 (17.1 %) and unclassified/papillary
subtype in 3 cases (11.5 %). Prognostic criteria using
ECOG performance status were 0 in 29 patients (83 %)
and >1 in the remaining 6 patients (17 %). The complete
list of patient characteristics is shown in Table 1 without
relevant differences regarding general and oncological
characteristics between the groups.
Most RCCLM were metachronous (n = 29; 82.9 %); the
median time interval between the diagnosis of primary
tumor and the occurrence of first metastases was
13 months (IQR: 3–36 months), 15 months (IQR: 3–39
months) between primary tumor operation and occur-
rence of liver metastases. The median time between last
staging and liver surgery was 1 month (IQR: 0–2 months).
The mean number of hepatic metastatic lesions was 1.7
(range: 1–5) being localized unilobular in the liver (n = 28,
80 %). The median size of the largest lesion was 4.4 cm
(IQR: 2.9 – 6.0 cm).
Details of liver-directed therapy
Among the 35 patients with RCCLM, liver-directed
treatment consisted of liver resection in 33 patients
(94.3 %) and local ablation in 2 patients (5.7 %) (Table 2).
In the resection-group, 16 of 35 patients (48.5 %) under-
went major liver resections, in 17 patients (51.5 %)
minor liver resections were performed. On final patho-
logic analysis, local R0 (margin free) resection could be
achieved in 30 patients (85.7 %); only 5 patients (14.3 %)
had microscopic disease at the margin (R1) and none pa-
tient had macroscopic disease (R2).
Median operating time was 238 min (IQR: 161.5–276
min), median ICU and hospital stay were 1.9 days (IQR: 1–
6 days) and 18.7 (IQR: 11–28 days), respectively.
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Postoperative complications were classified according to
the Clavien-Dindo Classification, with an overall postopera-
tive morbidity in 10 patients (28.5 %). In this context, minor
complications (grade I, n =0; 0 %; grade II, n = 3; 8.6 %)
were observed in 3 patients (8.6 %), major complications
occurred in 7 patients (19.9 %) (grade IIIa, n = 5, 14.3 %;
grade IIIb, n = 1, 2.9 %; grade IV, n = 1, 2.9 %; grade V, n =
0; 0 %). The 30-day mortality of the study group was 0 %.
Treatment after resection of metastatic lesions/recurrence
analysis
At time of liver-directed therapy, the liver was the first
and only metastases in 28 patients (n = 80 %). Whereas,
there was evidence of extrahepatic disease in 7 patients
(20 %). These metastases were surgically treated with
curative intention before liver resection, or were syn-
chronously discovered at laparotomy and subsequently
resected. The most common sites of metastases were the
retroperitoneum/local recurrence (n = 5; 14.3 %), the
lung (n = 2; 5.7 %), the adrenal glands (n = 2; 5.7 %) and
the bone (n = 1; 2.8 %).
A total of 16 patients (41 %) received TKI therapy fol-
lowing liver-directed therapy of their metastatic hepatic
lesions after a median duration of 2.4 months (IQR: 1–5
months) (Fig. 1). In 3 patients a preoperative targeted
therapy was started with median duration of 2.1 months
Table 1 Basic general and oncological characteristics according to state of postoperative Tyrosinkinase Inhibitor (TKI) therapy
Variables Overall (n = 35) TKI (+) (n = 16) TKI (-) (n = 19) p-value
Median Age (years) 65 (59–71) 64.5 (58–71) 69 (62–71) 0.160a
Gender 24:11 12:4 12:7 0.452d
Male/female (68.6/31.4 %) (34.3:11.4 %) (34.3:20 %)
Median Body mass index (kg/m2) 26.5 (24.5–28.0) 26.9 (26.0–28.3) 25.9 (24.2–27.7) 0.349a
ECOG performance status (%)
0 29 (82.9 %) 15 (42.9 %) 14 (40 %) 0.117d
1 6 (17.1 %) 1 (2.9 %) 5 (14.3 %)
Primary tumor characteristics
Right side/left side; n (%) 21/14 (60 %:40 %) 7/9 (20 %:25.7 %) 14/5 (40 %:14.3) 0.072d
Primary tumor histology
Clear cell 25 (71.4 %) 10 (28.6 %) 15 (42.9 %) 0.283c
Non-clear cell 10 (28.6 %) 6 (17.1 %) 4 (11.5 %)
Primary tumor T-stage
Stage 1–2 16 (45.8 %) 8 (22.9 %) 8 (22.9 %) 0.640c
Stage 3–4 19 (54.2 %) 11 (31.3 %) 8 (22.9 %)
Primary tumor grading
Low (Fuhrmann 1–2) 24 (68.6 %) 12 (34.3 %) 12 (34.3 %) 0.452d
High (Fuhrmann 3–4) 11 (31.4 %) 4 (11.4 %) 7 (20 %)
Liver tumor distribution
Unilobular/Multilobular 28:7 (80 %:20 %) 14:2 (40 %:14.3 %) 14:5 (40 %:5.7 %) 0.309d
Median tumor size (cm) 4.4 (2.9–6.0) 3.9 (2.5–4.5) 5.6 (3.0–7.5) 0.094a
Mean number of hepatic tumor lesions 1.70 (1–5) 1.64 (1–4) 1.74 (1–5) 0.813b
Median weight of resected liver (g) 212.5 (39.2–652.5) 81.4 (15.5–265.0) 290 (70–916.3) 0.138a
Timing of liver metastases
Synchronous/ 6 (17.1 %) 4 (11.4 %) 2 (5.7 %) 0.258d
metachronous 29 (82.9 %) 12 (34.3) 17 (48.6 %)
Extrahepatic disease at time of liver-directed therapy
Yes 7 (20 %) 5 (14.3 %) 2 (5.7 %) 0.127d
No 28 (80 %) 11 (31.4 %) 17 (48.6 %)
Used statistical tests:
aStudent’s t-test
bWilcoxon rank sum test
cchi-squared test
dFisher’s exact test
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(IQR: 1–25 months) and continued after liver-directed
therapy. The given targeted therapy included sunitinib
(n = 10 patients; 62.5 %), sorafenib (n = 2 patients; 12.5 %),
pazopanib (n = 3 patients; 18.8 %) and everolimus (n = 1
patient; 6.2 %).
Of these 16 patients, 10 patients (28.5 %) had on-
going TT after liver-directed therapy for a median
duration of 21 months (IQR: 18–49 months) and 6
patients (17.1 %) discontinued TT therapy at a me-
dian duration of 13 months (IQR: 7–35 months)
without evidence of recurrence. Of the 10 patients
with ongoing TT after liver-directed therapy, 4 pa-
tients (40 %) experienced relapse/recurrence. Of the
6 patients discontinued TT, 5 patients (83 %) experi-
enced relapse/recurrence.
Of the 19 patients (59 %), who did not receive imme-
diate postoperative targeted therapy, 14 patients (74 %)
experienced recurrence after a median time of 11 months
(IQR: 4–31 months). In total, 23 patients (66 %) did de-
velop recurrence following LDT within a median time of
16 months (IQR: 5–34 months). Among these patients,
the pattern of recurrence was extrahepatic in 13 patients
(57 %), intrahepatic in 7 patients (30 %) and both in 3
patients (13 %). At the end of the observation period, 20
patients (57 %) had died. Of the 15 patients (43 %) alive,
8 patients (54 %) remained free of recurrence after a me-
dian follow-up of 2.1 years (range: 1–4.3 years). Of the 7
patients (43 %) developed recurrence, only 2 patients
had local metastases in the pre-existing site. Lung me-
tastases were developed most frequently (n = 4), followed
Table 2 Operative and perioperative details at time of liver-directed therapy of our study population (n = 35 patients) according to
state of Tyrosinkinase Inhibitor (TKI) Therapy
Variables Total (n = 35) TKI+ (n = 16) TKI- (n = 19) p-value
Extent of resection
Minor resection 17 (51.5 %) 11 (33.3 %) 6 (18.2 %) 0.008d
Major 16 (48.5 %) 3 (9.1 %) 13 (39.4 %)
Type of liver resection
Segmental resection 9 (27.3 %) 6 (18.2 %) 3 (9.1 %) 0.13d
Anatomical right/left resection 11 (33.3 %) 9 (27.2 %) 2 (6.1 %) 0.003d
Extended resection right/left 5 (15.2 %) 4 (12.1 %) 1 (3.1 %) 0.06d
Atypical resection 8 (24.2 %) 4 (12.1 %) 4 (12.1 %) 0.61d
Resection Margin
Complete Resection (R0) 30 (85.7 %) 14 (40 %) 16 (45.7 %) 0.78d
Microscopically positive margin (R1) 5 (14.3 %) 2 (5.7 %) 3 (8.6 %)
Transfusion intraoperative
Substitution 15 (8 %) 9 (4.8 %) 3 (1.6 %) 0.7d
- Transfusion erythrocyte concentrations 0.27 (0–6) 0.23 (0–6) 0.36 (0–4) 0.7d
- Transfusion Fresh frozen plasma 0.17 (0–8) 0.2 (0–8) 0.03 (0–1) 0.7d
Pringle manoeuvre 19 (54.3 %) 6 (17.1 %) 13 (37.1 %) 0.067c
Median Hospital stay (days) 18.7 (11–28) 16.6 (11–18) 20.5 (16–24) 0.360a
Median Intensive care unit stay (days) 1.9 (1–6) 2.0 (1–6) 1.8 (1–5) 0.716a
Median Operating time (min) 238 (161.5–276) 224.5 (164.5–272.5) 242 (155–281) 0.477a
Complications
Grade I 0 (0 %) 0 (0 %) 0 (0 %) -
Grade II 3 (8.6 %) 2 (5.7 %) 1 (2.9 %) 0.434d
Grade IIIa 5 (14.3 %) 4 (11.4 %) 1 (2.9 %) 0.096d
Grade IIIb 1 (2.9 %) 0 (0 %) 1 (2.9 %) 0.352d
Grade Iva 1 (2.9 %) 1 (2.9 %) 0 (0 %) 0.269d
Grade IVb 0 (0 %) 0 (0 %) 0 (0 %) -
Grade V 0 (0.5 %) 0 (0 %) 0 (0 %) -
Used Statistical tests:
aStudent’s t-test
bWilcoxon rank sum test
cchi-squared test
dFisher’s exact test
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by the liver (n = 2) and the bone (n = 1). Sites of recur-
rence were not different according to the immediate
postoperative TKI therapy.
Median progression-free survival and median disease-
free survival was 27 months (IQR: 8–47 months; median
follow-up was 3.1 years (IQR: 1.1–4.8 years)) following
resection of first metastatic lesions and 19 months (IQR:
7–58 months; median follow-up was 2.1 years (IQR: 1–
4.3 years)) following LDT, respectively. One-, 3-, and 5-
year progression-free survival following resection of first
metastases was 60, 28.6 and 11.4 %, respectively. Follow-
ing LDT, 1-, 3- and 5-year disease-free survival was 60,
22.9 and 14.3 %, respectively.
In univariate analysis for progression-free survival,
immediate postoperative targeted therapy (p = 0.023)
(Fig. 2), ECOG performance status 0 (p = 0.015), meta-
chronous liver metastases (p = 0.035), negative resec-
tion margins (p = 0.001), T-stage 1/2 (p = 0.027) and
low Fuhrman Grading (p = 0.002) were associated with
significantely longer progression-free survival rates
(Table 3). At multivariable Cox regression analysis, im-
mediate postoperative targeted therapy (HR 0.32, 95 CI:
0.1–0.9, p = 0.032) could be identified as a favourable
significant independent predictor of good progression-
free survival. In contrast, ECOG performance status >1
(HR 3.4, 95 CI 1.2–9.8, p = 0.023) could be identified as
independent significant predictor associated with dis-
ease progression.
Following factors show benefitial effects on disease-
free survival in univariate analyses: Negative resection
margins (p = 0.014) and low Fuhrman grading (p =
0.001) (Table 4). Immediate postoperative TKI therapy
(p = 0.1), ECOG status 0 (p = 0.1), metachronous liver
metastases (p = 0.08) and T-stage 1/2 (p = 0.07), however,
showed only a trend for a decreased recurrence rate in
univariate analysis.
Survival analysis
Median overall survival was 86 months (IQR: 21 –
136 months; median follow-up was 5.1 years (IQR: 1.8 –
8.0 years) following primary tumor resection and
42 months (IQR: 18 – 98 months; median follow-up was
2.2 years (IQR: 1 – 4.8 years) following LDT, respect-
ively. One-, 3-, and 5-year survival following resection of
the primary tumor was 88.6, 68.6 and 51.4 %, respect-
ively. Following LDT, 1-, 3- and 5-year survival was 77.1,
45.7 and 20 %, respectively.
In the univariate analysis using the Kaplan-Meier
Method, immediate postoperative TKI therapy (p =
0.032) (Fig. 3), ECOG performance status 0 (p < 0.001),
metachronous liver metastases (p = 0.006), liver tumor
size <45 mm (p = 0.007), negative resection margins (p =
0.013) and a disease free survival >12 months (p = 0.002)
were significant predictors of good overall survival fol-
lowing liver-directed therapy (Table 4).
Multivariate survival analysis using a Cox regression
model showed that immediate postoperative TKI therapy
(HR 0.28, 95CI: 0.1–0.99, p = 0.046) was a favourable sig-
nificant independent predictor of good overall survival.
Whereas ECOG performance status >1 (HR 4.6, 95 CI
1.4–14.7, p < 0.001) and synchronous liver metastases (HR
5.7 95 CI 1.4–23.8, p = 0.015) are significant independent
predictors of poor overall survival. Whereas, multiple liver
Fig. 1 Treatment algorithm of patients with hepatic metastasized renal cell cancer following liver-directed therapy
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metastases (HR 1.1; 95 CI 0.4–2.9, p = 0.8) were no signifi-
cant independent predictors of overall survival.
Following primary tumor resection, in univariate ana-
lysis immediate postoperative TKI therapy (p = 0.003),
ECOG performance status 0 (p < 0.001), metachronous
liver metastases (p = 0.006), liver tumor size <45 mm (p =
0.007) and negative resection margins (p = 0.041) were of
prognostic impact on good overall survival. Multivariate
analysis using a Cox regression model confirmed immedi-
ate postoperative TKI therapy (HR 0.14, 95 CI: 0.03–0.6,
p = 0.011) as a favourable significant independent pre-
dictor of good overall survival. In contrast, ECOG per-
formance status >1 (HR 8.3, 95 CI 1.9–18.7, p < 0.001)
and synchronous liver metastases (HR 5.4 95 CI 1.1–26.8,
p = 0.013) are significant independent predictors of poor
overall survival.
Discussion
To our best knowledge, this is one of the largest studies
examining the value of metastasectomy with a special
focus on liver resection in patients with MRCC in the
era of TKI therapy. We examined whether TKI therapy
is associated with MRCC prognosis when it is provided
immediately after surgical resection of metastatic hepatic
lesions. Uni- and multivariate analyses showed that me-
dian overall survival such as progression-free survival
were significantly better in patients receiving immediate
postoperative TKI therapy following primary tumor re-
section and LDT, respectively. However, disease recur-
rence following liver resection showed only a trend to be
less common in patients who received immediate post-
operative TKI therapy. These results could be a sign that
immediate postoperative TKI therapy improves survival
and disease control by decreasing tumor recurrence fol-
lowing resection of metastatic hepatic lesions.
Various treatment options have been studied for the
therapy of MRCC and the benefits of metastasectomy in
these patients could be demonstrated in some retro-
spective studies [7, 8, 29]. In this context, there is emer-
ging evidence that surgical resection may represent a
significant tool in multimodal concepts of MRCC. In
accordance with retrospective studies, our study dem-
onstrates liver resection to be safely applicable with
comparable survival and recurrence rates for patients
with resectable RCCLM [6, 10, 11, 13, 30]. Therefore,
selected clinical characteristics and patient-defined var-
iables have been determined to stratify risk for metasta-
sectomy in MRCC patients to help to define groups of
patients which benefit most from surgical therapy with
a focus on liver metastasectomy. In accordance with
previous reports, in our study immediate postoperative
TKI therapy, ECOG performance status, timing of liver
metastases presence, tumor diameter, primary tumor
characteristics (Fuhrman Grading, T-Stage,), negative
resection margins and time of disease free interval were
of prognostic value for overall survival and recurrence
[6, 10, 11, 25, 30–33].
However, the prognostic value of Fuhrman grading
in papillary renal cancer is inconsistent and nowdays
not considered as the best grading system for non-
clear cell renal cancer. In recent studies, nuclear grade
seems to be more effective to predict outcome in pa-
tients with non-clear cell renal cancer [34]. Other fac-
tors like patients’ age, number of metastases, presence
Fig. 2 Kaplan-Meier survival curve representing progression-free survival after first metastasectomy according to immediate postoperative
tyrosinkinase inhibitor therapy (p = 0.023)
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Table 3 Univariate analysis of potential prognostic factors for progression-free survival (n = 35 patients) and disease-free survival
(n = 35 patients) following metastasectomy of primary and hepatic metastasic lesions, respectively
Progression-free Survival after
first Metastasectomy
Disease-free Survival after Liver-directed
therapy (LDT)
Variables n Median Time (months) with IQR p-value Median Time (months) with IQR p-value
Gender
Male 24 8 (5–44) 0.324 15 (5–44) 0.346
Female 11 27 (10–47) 20 (9–58)
Targeted therapy
TKI+ 16 47 (18–79) 0.023 58 (18–79) 0.110
TKI– 19 19 (6–39) 19 (4–46)
ECOG
0 29 29 (10–47) 0.015 20 (8–71) 0.132
> 1 6 6 (2–28) 15 (1–28)
Age
< 65 years 18 19 (8–40) 0.518 19 (5–71) 0.960
> 65 years 17 39 (8–71) 20 (9–58)
Tumor distribution
unilobular 28 28 (8–44) 0.772 28 (8–58) 0.981
multilobular 7 19 (3–77) 19 (3–79)
Extrahepatic Disease
Yes 28 27 (7–45) 0.412 19 (8–59) 0.962
No 7 29 (4–82) 20 (4–29)
Liver metastasis Timing
Synchronous 6 4 (2–9) 0.035 4 (2–8) 0.085
Metachronous 29 28 (10–47) 26 (12–58)
Tumor size, cm
< 4.5 cm 21 39 (10–71) 0.07 19 (9–42) 0.376
> 4.5 cm 14 18 (6–29) 18 (5–35)
Resection margin
Radical resection (R0) 30 28 (12–51) 0.001 28 (12–58) 0.014
Irradical resection (R1/R2) 5 6 (3–10) 4 (3–9)
Number of metastases
Solitary 22 27 (8–47) 0.653 28 (9–51) 0.967
Multiple 13 19 (8–40) 19 (5–79)
Grading of RCC
Low (G1/G2) 24 40 (18–71) 0.002 44 (18–71) 0.001
High (G3/G4) 11 8 (5–19) 8 (4–19)
T-stage
T1/T2 16 44 (12–79) 0.027 29 (15–71) 0.071
T3/T4 19 18 (6–39) 18 (4–51)
Disease-free intervall
< 12 months 17 28 (5–79) 0.753 28 (5–79) 0.501
> 12 months 18 27 (10–40) 19 (9–58)
TKI Tyrosinkinase InhibitorTherapy, ECOG Eastern Cooperative Oncology Group
The bold data specifies a staticial significance p-values < 0.05
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of synchronous extrahepatic disease such as factors related
to tumor biology might help to decide to operate or not.
Overall, approximately 70 % (25/35) of our patients
experienced disease recurrence after surgical resection
of first metastatic lesions. Our results are consistent with
previous studies which have shown that large numbers
of patients experience disease recurrence after metasta-
sectomy with excellent cancer-specific overall survival.
Johansen et al. reported that disease recurrence was ob-
served in 66.7 % of patients, with complete response
achieved by targeted therapy alone or no evidence of
disease with additional metastasectomy after a median
follow up of 12 months [35]. More recently, Park et al.
reported about disease recurrence in 60.4 % of patients
received immediate postoperative targeted therapy after
metastasectomy or not over a median follow-up of
12 months [27]. These results confirmed the fact that
some residual cancer cells might remain after the
complete resection of metastatic lesions.
Some clinical trials showed that advanced RCC is often
resistant to most systemic therapies, and shows limited
response to immunotherapy [8, 16]. Recently, several
randomized controlled trials have shown that TKI like
sorafenib, sunitinib or pazopinib, and other targeted
therapeutical agents are correlated with improvements
in PFS and OS [20, 21, 36, 37]. These new drugs have
dramatically changed the treatment and prognosis of pa-
tients with MRCC, and give the opportunity to perform
metastatic resection in a new and expended population
of patients as more response has been noted. However,
cure is rare with TKI alone and complete remission after
TKI treatment occurs in only 1–3 % of cases [18, 19].
Whereas, partial response could be achieved in 10–39 %
of patients, and ceiling of the overall survival was
18.8 months (range 7.8 to 43.2 depending of the risk fac-
tors) [35, 38, 39]. Therefore, metastasectomy remains an
important treatment for MRCC and the growing evi-
dence of long-term response with TKI therapy has been
stimulating multimodal approaches in the last years.
However, there is currently low experience with the
role of systemic TT after surgical treatment of metastatic
lesions in patients with RCC and experience is based on
case reports and small series [8, 22, 26, 40]. Reliable data
examining patients with RCCLM following liver resec-
tion are completely missing. The largest series was pub-
lished recently by Park et al. who examined the efficacy
of adjuvant targeted therapy after complete resection of
metastatic lesions in 53 patients with MRCC; however
none of the patients had RCCLM. 19 (35.9 %) of the
patients received immediate postoperative targeted
therapy. Of the 34 who did not receive immediate post-
operative targeted therapy, 27 (79.4 %) experienced dis-
ease recurrence. Immediate postoperative targeted therapy
was associated with better median progression free survival
(not reached versus 20.0 months, p = 0.017), but not
cancer-specific survival [27]. According to the missing
available data, prospective, randomized multicentre clinical
trials (RESORT Study and SMAT-AN 20/04 of the
Working Group of Urological Oncology (AUO)) were
initiated within the last years to studying the effects
and benefits of targeted adjuvant therapy following
metastasectomy [18, 41, 42].
Fig. 3 Kaplan-Meier overall survival curve representing follow-up after liver-directed therapy according to immediate postoperative tyrosinkinase
inhibitor therapy (p = 0.032)
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Table 4 Univariate analysis of potential prognostic factors for overall Survival (n = 35 patients) following primary tumor resection
and liver directed therapy (LDT) , respectively
Follow-Up Liver-directed therapy Follow-Up Primary Tumor Resection
Variables n Median Time (months) with IQR p-value Median Time (months) with IQR p-value
Gender
Male 24 42 (21–98) 0.7 96 (34–130) 0.4
Female 11 37 (12–68) 62 (63–126)
Targeted therapy
TKI+ 16 98 (57–133) 0.032 151 (126–202) 0.003
TKI− 19 40 (12–64) 61 (25–103)
ECOG
0 29 57 (37–98) 0.001 103 (79–151) <0.001
> 1 6 12 (9–18) 15 (13–34)
Age
< 65 years 18 64 (35–98) 0.07 96 (34–151) 0.31
> 65 years 17 40 (12–57) 63 (79–126)
Tumor distribution
unilobular 28 98 (21–76) 0.911 126 (25–151) 0.8
multilobular 7 42 (12–98) 86 (54–126)
Synchronous Extrahepatic Disease
Yes 7 21 (9–37) 0.312 63 (54–126) 0.727
No 28 47 (28–98) 86 (61–159)
Liver metastasis Timing
Synchronous 6 9 (8–12) 0.006 15 (8–63) 0.006
Metachronous 29 47 (28–98) 96 (54–151)
Tumor size, cm
< 45 mm 21 98 (28–133) 0.007 103 (86–151) 0.007
> 45 mm 14 37 (12–57) 63 (18–85)
Resection margin
Radical resection (R0) 30 47 (21–98) 0.013 96 (48–151) 0.041
Irradical resection (R1/R2) 5 9 (8–28) 86 (13–92)
Number of metastases
Solitary 22 64 (12–98) 0.850 85 (54–153) 0.990
Multiple 13 42 (21–76) 116 (34–130)
T-stage
T1/T2 16 47 (37–98) 0.062 126 (62–151) 0.257
T3/T4 19 40 (12–64) 85 (54–103)
Grading of RCC
Low (G1/G2) 24 47 (37–133) 0.543 116 (63–126) 0.501
High (G3/G4) 11 28 (9–98) 85 (51–151)
Disease-free intervall
< 12 months 17 13 (9–42) 0.002 79 (18–96) 0.2
> 12 months 18 64 (42–98) 103 (62–151)
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Nevertheless, there are some limitations to our study.
Firstly, it concerns a small patient sample and due to the
retrospective nature of our study it is susceptible to bias
in data selection and survival analysis. Although our re-
sults show significant differences in overall survival (OS)
and progression-free survival (PFS), we could not find
significant differences in disease-free survival (DFS),
which at first sight might seem astonishing. The three
outcome variables are very distinct from each other and
may not readily be compared as they include different
patients. Also, regarding the trends in the data, the fol-
low up might have been to short to show differences in
terms of DFS. Unfortunately, the sample size was too
small to allow a final answer to our hypotheses.
Secondly, there are no comparative studies in this highly
selected patient population which examine patients with
MRCC without surgical intervention who were treated
with targeted therapy. Thirdly, there were no standard
protocols for the clinical decision making process con-
cerning the choice of given targeted agents as well as the
timing of restarting or discontinuating the targeted ther-
apy. This fact is especially mirrored in our study because
of the long observation period of 23 years. For our first pa-
tients TKI therapy was not yet available. During the next
period, several publications about the use of TKI in differ-
ent clinical settings influenced the decision of our interdis-
ciplinary tumor board to use or avoid additional TKI after
surgery, respectively. Furthermore, in patients with R1 re-
section and higher tumor stages the decisions in favour of
using TKI were influenced more positively compared to
lower tumor stages. Therefore differences in survival
might also be due to some selection bias. Of interest, data
on patient Quality of Life (QoL) might be an important
addition in future studies for the results of our analysis.
Conclusions
The present data suggest that a surgical approach of
MRCC to the liver in combination with adjuvant TKI
therapy should be carefully considered case-by-case, tak-
ing into account patient QoL in order to optimize the
management of these patients. However, future pro-
spective studies, preferably with randomized design and
larger populations, are needed do increase the quality of
evidence regarding the role of (liver-)metastasectomy
with integration of TKI therapy in the (neo)/-adjuvant
setting. Moreover, a careful balance of the benefit/risk
ratio must be shared among a multidisciplinary team
to tailor treatments individually and with the patient.
Therefore, prognostic models and algorithms might in-
deed help in deciding which patients benefit from
(liver-) metastasectomy as an additive tool in the
multimodal therapeutical setting of MRCC.
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